FY2020 EPS Estimates for Amarin Co. plc (AMRN) Cut by Jefferies Group

Amarin Co. plc (NASDAQ:AMRN) – Analysts at Jefferies Group lowered their FY2020 earnings per share (EPS) estimates for shares of Amarin in a research report issued to clients and investors on Wednesday. Jefferies Group analyst M. Andrews now anticipates that the biopharmaceutical company will post earnings of $0.07 per share for the year, down from their prior forecast of $0.08. Jefferies Group currently has a “Buy” rating on the stock. Jefferies Group also issued estimates for Amarin’s FY2021 earnings at $0.19 EPS.

A number of other research firms also recently issued reports on AMRN. Zacks Investment Research downgraded shares of Amarin from a “hold” rating to a “sell” rating in a research note on Wednesday. ValuEngine upgraded shares of Amarin from a “sell” rating to a “hold” rating in a research note on Wednesday. BidaskClub upgraded shares of Amarin from a “sell” rating to a “hold” rating in a research note on Thursday. Cantor Fitzgerald set a $10.00 target price on shares of Amarin and gave the company a “buy” rating in a research note on Tuesday. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Amarin in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. Amarin presently has an average rating of “Hold” and an average price target of $7.75.

Amarin (NASDAQ:AMRN) traded up $0.13 during midday trading on Thursday, hitting $4.09. 1,910,000 shares of the stock were exchanged, compared to its average volume of 1,510,000. The company has a current ratio of 1.63, a quick ratio of 1.32 and a debt-to-equity ratio of -1.48. Amarin has a 1 year low of $2.81 and a 1 year high of $4.47. The company has a market capitalization of $1,140.00, a P/E ratio of -15.15 and a beta of 0.66.

Amarin (NASDAQ:AMRN) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $45.85 million. During the same period last year, the company earned ($0.08) EPS. The firm’s revenue for the quarter was up 45.4% on a year-over-year basis.

In other news, insider Steven B. Ketchum sold 63,479 shares of Amarin stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $3.48, for a total transaction of $220,906.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John F. Thero acquired 10,000 shares of the stock in a transaction dated Thursday, November 30th. The shares were bought at an average price of $3.24 per share, with a total value of $32,400.00. The disclosure for this purchase can be found here. 3.72% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the company. Westside Investment Management Inc. lifted its stake in shares of Amarin by 1.1% during the second quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 300 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Amarin by 15.2% during the second quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company’s stock worth $152,000 after purchasing an additional 5,000 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Amarin during the third quarter worth $226,000. Stevens Capital Management LP purchased a new position in shares of Amarin during the third quarter worth $229,000. Finally, Stonepine Capital Management LLC purchased a new position in shares of Amarin during the second quarter worth $302,000. Institutional investors and hedge funds own 40.12% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.com-unik.info/2017/12/23/fy2020-eps-estimates-for-amarin-co-plc-amrn-cut-by-jefferies-group.html.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Earnings History and Estimates for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit